Antiphospholipid antibodies associated with nodal marginal zone lymphoma and its progression to diffuse large B-cell lymphoma—A case report

Belančić, Andrej; Vranić, Luka; Ševeljević, Ivan; Hadžisejdić, Ita; Načinović, Antica Duletić; Jonjić, Nives

doi:10.1016/j.prp.2018.10.020

Cited by 4 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The current research is thus the first to report on Asian patients with lymphoma; furthermore, it used a prospective cohort design and enrolled a large number of patients. Although a number of case reports have demonstrated an association between aPLs and lymphoma, 23 – 26 most of the lymphoma subtypes hitherto published have been MZL. This could be explained theoretically by its unique, plasmacytic-differentiation characteristic.…”

Section: Discussionmentioning

confidence: 99%

High Incidence of Antiphospholipid Antibodies in Newly Diagnosed Patients With Lymphoma and a Proposed aPL Predictive Score

Kungwankiattichai

Nakkinkun

Owattanapanich

et al. 2020

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

Given that the presence of antiphospholipid (aPL) antibodies has been proposed to be associated with thrombosis in newly diagnosed patients with lymphoma, we conducted a prospective cohort study on these patients. In all, 154 patients were enrolled. More than half were advanced-stage diffuse large B-cell lymphoma. Approximately one-third (35.7%) of the patients had the presence of aPLs, with single-, double-, and triple-aPL positivities of 29.9%, 5.2%, and 0.6%, respectively. Of the 154 patients, 8 (5.19%) developed symptomatic thrombosis during follow-up. There were no significant differences in the incidences of thrombosis for the aPL-positive and aPL-negative groups (5.5% vs 5.1%; P = 1.000). In a multivariate analysis, patients with male sex and lymphoma stage IV were significant risk factors for aPL positivity, with odds ratio [OR] = 2.22 (95% CI: 1.11-4.45), P = .025, and OR: 2.34 (95% CI: 1.17-4.67), P = .016, respectively. An aPL predictive score of ≥−1 was predictive of aPL positivity, with a sensitivity of 83.6% and specificity of 34.3%.

show abstract

Section: Discussionmentioning

confidence: 99%

High Incidence of Antiphospholipid Antibodies in Newly Diagnosed Patients With Lymphoma and a Proposed aPL Predictive Score

Kungwankiattichai

Nakkinkun

Owattanapanich

et al. 2020

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

show abstract

“…It can arise in various organs, especially the stomach, lungs and ocular adnexa 4 . This draws our attention as it has never been documented that individuals with APS could progress to EMZL previously, even though there was an association between the development of aPL antibodies and other lymphoproliferative diseases 5 . Here, we aimed to determine the underlying mechanism leading to the progression of APS to EMZL in this patient.…”

Section: Figurementioning

confidence: 90%

“…4 This draws our attention as it has never been documented that individuals with APS could progress to EMZL previously, even though there was an association between the development of aPL antibodies and other lymphoproliferative diseases. 5 Here, we aimed to determine the underlying mechanism leading to the progression of APS to EMZL in this patient. After inquiring about the medical history, we knew that the patient had been immunized against inactivated coronavirus disease 2019 (COVID-19) vaccine just 2 days (May 30, 2021) before his relapsing severe thrombocytopenia (Figure 1A).…”

mentioning

confidence: 99%

A20 haploinsufficiency caused by loss‐of‐function TNFAIP3 mutation likely leads to progression of antiphospholipid syndrome to marginal zone lymphomas following coronavirus disease 2019 vaccination: A case study

et al. 2023

Clinical and Translational Dis

View full text Add to dashboard Cite

This short communication describes a rare case of an antiphospholipid syndrome patient who progressed to extranodal marginal zone lymphomas following the coronavirus disease 2019 vaccination. The patient carried a novel heterozygous mutation in the TNFAIP3 gene which encoded A20, a key molecule controlling NF-κB signalling. This variation led to the production of a loss-of-function A20 Lys148fs*67, which lost the ability to inhibit inflammation.

show abstract

Concomitant manifestations of systemic lupus erythematosus flare‐up and nodal marginal zone B‐cell lymphoma in a 41‐year‐old male patient: A challenging case report

Zarafshani,

Rahmanian,

Manouchehri Ardekani

et al. 2024

Clinical Case Reports

View full text Add to dashboard Cite

Key Clinical MessageMalignancy may be a possible cause of systemic lupus erythematosus (SLE) flare‐ups, and it is necessary to consider it in the context of treatment resistance. In this case, we present a challenging instance of concomitant nodal marginal zone B‐cell lymphoma (NMZL) and SLE flare‐up in a 41‐year‐old male patient.AbstractSystemic lupus erythematosus (SLE) is a chronic autoimmune disease that can cause various symptoms and affect multiple organs in the body. It is also associated with the development of malignancies, especially lymphomas. This case report discusses a patient who experienced a flare‐up of SLE along with hypercalcemia, which led to the diagnosis of nodal marginal zone B‐cell lymphoma (NMZL). This is the first case of its kind to be reported. A 41‐year‐old man with a 10‐year history of SLE and antiphospholipid syndrome (APS) was referred to our center due to several symptoms, including fatigue, oral lesions, dyspnea, bilateral wrist pain and inflammation, mild pericardial effusion, organ enlargement, pancytopenia, high erythrocyte sedimentation (ESR) level, high anti‐double stranded DNA (anti‐dsDNA) level, low complement level, resistant hypercalcemia, and high brain natriuretic peptide (pro‐BNP) level. After further testing, it was discovered that the patient had NMZL, which was the ultimate diagnosis. He underwent six cycles of the R‐CHOP chemotherapy regimen, and his clinical and laboratory conditions improved during follow‐ups. The initial case of SLE flare‐up, with concomitant NMZL is being reported as the final diagnosis. In simpler terms, it is possible for lymphoma to manifest as a potential cause of SLE flare‐ups, and clinicians should be mindful that they need to consider malignant conditions when faced with treatment resistance.

show abstract

Antiphospholipid antibodies associated with nodal marginal zone lymphoma and its progression to diffuse large B-cell lymphoma—A case report

Cited by 4 publications

References 26 publications

High Incidence of Antiphospholipid Antibodies in Newly Diagnosed Patients With Lymphoma and a Proposed aPL Predictive Score

High Incidence of Antiphospholipid Antibodies in Newly Diagnosed Patients With Lymphoma and a Proposed aPL Predictive Score

A20 haploinsufficiency caused by loss‐of‐function TNFAIP3 mutation likely leads to progression of antiphospholipid syndrome to marginal zone lymphomas following coronavirus disease 2019 vaccination: A case study

Concomitant manifestations of systemic lupus erythematosus flare‐up and nodal marginal zone B‐cell lymphoma in a 41‐year‐old male patient: A challenging case report

Contact Info

Product

Resources

About